Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shares fell 3.8% on Thursday . The stock traded as low as $2.01 and last traded at $2.02, with a volume of 64,557 shares. The stock had previously closed at $2.10.

Several brokerages recently weighed in on EYEG. Maxim Group reaffirmed a “hold” rating on shares of Eyegate Pharmaceuticals in a research report on Tuesday, June 28th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Monday, June 13th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 14th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Eyegate Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $9.00.

The stock’s 50 day moving average is $2.50 and its 200 day moving average is $2.98. The company’s market capitalization is $17.44 million.

In other Eyegate Pharmaceuticals news, major shareholder Ventech Capital Ii sold 29,400 shares of Eyegate Pharmaceuticals stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $3.25, for a total transaction of $95,550.00. Following the transaction, the insider now directly owns 1,641,540 shares in the company, valued at approximately $5,335,005. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Morton Goldberg sold 15,000 shares of Eyegate Pharmaceuticals stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $3.16, for a total transaction of $47,400.00. Following the transaction, the director now owns 17,277 shares in the company, valued at $54,595.32. The disclosure for this sale can be found here.

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.